BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A

FDA No Longer Plans to Hold an Advisory Committee Meeting, as Previously Planned, to Discuss the Biologics License Application (BLA) BioMarin Remains on Track to Host Scheduled Manufacturing Inspections by FDA in the Coming Weeks SAN RAFAEL, Calif., Nov. 23, 2022 /PRNewswire/ -- BioMarin...

Click to view original post